Amring Pharmaceuticals Inc, a subsidiary of Nordic Group B.V. (Nordic Pharma), has selected a new chief operating officer (COO) and named four eyecare professionals (ECPs) to its medical advisory board.
Let’s start with this company.
Founded in 2015 and based in Berwyn, Pennsylvania, Amring Pharmaceuticals is a privately-held pharmaceutical manufacturing company offering niche generic formulations and “value-driven brands” to the market.
Amring also maintains partnerships with global biopharmaceutical companies to deliver biotechnology-based medicines.
Its parent company, Nordic Pharma, is a United Kingdom-based, privately-owned marketing and sales pharmaceutical company focused on the development and commercialization of specialty products in a number of therapeutics areas—including ophthalmology.
Didn’t we just hear news from Amring?
We did! In December 2023, the company (via Nordic Pharma) officially completed its acquisition of Visant Medical, Inc., a California-based clinical-stage medical device company.
Most notable about this purchase: Visant’s medical device for dry eye treatment called LACRIFILL, an FDA-cleared, cross-linked hyaluronic acid (HA)-based canalicular occlusive device designed to block tear drainage via occlusion of the canalicular system.
See here for our coverage (and details on LACRIFILL).
Now, who is this new COO?
Jai G. Parekh, MD, MBA, FAAO, will take over as COO, Eye Care US
With over two decades of eyecare clinical experience, Dr. Parkh is currently a clinical associate professor of Ophthalmology at the Icahn School of Medicine, NY, as well as CEO/co-founder of EyeCare Consultants of NJ in New Jersey.
He previously served as chief medical officer (CMO) at Allergan Eye Care.
So what will his focus be?
His top priority—as well as the company’s—is the anticipated US launch of LACRIFILL under the Nordic Pharma brand later this year. Dr. Parekh will be working with Phillip Gioia, president of the company’s US team, for the launch.
According to Nordic Pharma CEO Charlotte Phelps: “Dr. Parekh’s 25 years of eye care experience, strategic leadership, and deep understanding of eye care and the industry make him the perfect choice to guide our commercial entry into the US market.”
Gotcha. Lastly, who are these board members?
Per Amring, Nordic Pharma’s newly-formed US Medical Advisory Board members include: